Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $5.1 million.

  • Anika Therapeutics' Prepaid Assets fell 1083.1% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 1083.1%. This contributed to the annual value of $5.5 million for FY2024, which is 2651.15% down from last year.
  • As of Q3 2025, Anika Therapeutics' Prepaid Assets stood at $5.1 million, which was down 1083.1% from $5.3 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Prepaid Assets peaked at $10.5 million during Q1 2022, and registered a low of $5.1 million during Q3 2025.
  • Moreover, its 5-year median value for Prepaid Assets was $7.8 million (2023), whereas its average is $7.7 million.
  • Per our database at Business Quant, Anika Therapeutics' Prepaid Assets skyrocketed by 7048.95% in 2021 and then tumbled by 3427.89% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' Prepaid Assets stood at $8.3 million in 2021, then grew by 6.5% to $8.8 million in 2022, then fell by 15.31% to $7.5 million in 2023, then decreased by 26.51% to $5.5 million in 2024, then dropped by 6.64% to $5.1 million in 2025.
  • Its Prepaid Assets was $5.1 million in Q3 2025, compared to $5.3 million in Q2 2025 and $5.8 million in Q1 2025.